---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-002624"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-05-13T12:41:07+00:00"
generated_at: "2026-05-13T12:46:17.421261+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silexion begins GMP manufacturing of SIL204 with Catalent; Phase 2/3 trial approved at Israeli site

## Summary
- Initiated GMP clinical batch manufacturing of SIL204 with Catalent at its Limoges, France center of excellence.
- Tel Aviv Sourasky Medical Center Helsinki Ethics Committee approved planned Phase 2/3 trial of SIL204 in LAPC.
- SIL204 is a next-generation siRNA therapy targeting mutated KRAS, most common oncogenic driver in cancers.
- Phase 2/3 trial to evaluate SIL204 with standard-of-care chemo using dual-route (intratumoral + systemic) administration.
- Israeli Ministry of Health already approved the trial; CTA submitted to Germany; preparing for first patient dosing.

## SEC filing metadata
- accession: 0001178913-26-002624
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-05-13T12:41:07+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002624/0001178913-26-002624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002624/zk2635307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-002624
- JSON: https://secwatch.observer/filing/0001178913-26-002624.json
- Plain text: https://secwatch.observer/filing/0001178913-26-002624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.